Skip to main navigation

Search

Pre Header Links

Contact Us
Careers

Menu

Pre Header Links

Contact Us
Careers

About Us
Desktop - About Us
Pipeline
Desktop - Pipeline
- AT-007
- AT-001
- AT-003
- AT-104
- Clinical Trials
Patients & Caregivers
Desktop - Patients & Caregivers
Investors & Media
Desktop - Investor Menu

Mobile Header Links

About Us
Pipeline
- AT-007
- AT-001
- AT-003
- AT-104
- Clinical Trials
Patients & Caregivers
Investors & Media

Press Releases

Year

Mar 23, 2023

Applied Therapeutics Reports Fourth Quarter and Year-end 2022 Financial Results

Progress in Three Phase 3 Trials in Areas of High Unmet Clinical Need, Including Positive Sorbitol Reduction Data from the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) Deficiency On Track to Report Additional Phase 3 Data Across Multiple Programs in 2023 NEW YORK, March 23, 2023

Mar 01, 2023

Applied Therapeutics to Present at the Cowen 43rd Annual Health Care Conference

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will participate

Feb 16, 2023

Applied Therapeutics Announces Positive Sorbitol Reduction Data From the Ongoing Phase 3 INSPIRE Trial in Sorbitol Dehydrogenase (SORD) Deficiency

The ongoing Phase 3 INSPIRE trial is evaluating the effect of AT-007 vs. placebo in patients with SORD Deficiency on sorbitol reduction as well as clinical outcomes in approximately 50 patients age 16-55 in the US and Europe AT-007 reduced sorbitol by a mean of 52%, or approximately 16,000 ng/ml,

Feb 09, 2023

Applied Therapeutics to Present at the SVB Securities Global Biopharma Conference

NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present

Jan 04, 2023

Applied Therapeutics Announces Partnership with Advanz Pharma for Commercialization of AT-007 (Govorestat) in Europe

Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency Applied Therapeutics will receive milestone payments of over €130 million and 20% royalty payments on net sales in Europe

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 15 of 15

Print Page

Email Alerts

RSS Feeds

Contact IR

Footer New Links

About Us
Pipeline
Patients & Caregivers
Investors & Media

Menu

Footer New Links

About Us
Pipeline
Patients & Caregivers
Investors & Media

Footer Disclaimer Links

Terms of Use
Privacy Policy

Social Links

©2023 Applied Therapeutics All Rights Reserved

Social Links

Footer New Links

About Us
Pipeline
Patients & Caregivers
Investors & Media

Menu

Footer New Links

About Us
Pipeline
Patients & Caregivers
Investors & Media

Footer Disclaimer Links

Terms of Use
Privacy Policy

©2023 Applied Therapeutics All Rights Reserved